Name: Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood (Video) | JoVE Journal
Uploaded: 2020-02-05T13:00:00.000+00:00
Duration: 6 min 7 s
Description: Learn a flow cytometry assay to evaluate PD-1-blocking antibody binding to T cells using minimal peripheral blood from cancer patients. This method identifies immune subsets linked to therapeutic effects and adverse events.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by grants to S.K. from the Japan Society for the Promotion of Science KAKENHI (JP17K16045) and the Japan Agency for Medical Research and Development (JP18cm0106335 and 19cm0106310).

Sampling was performed during routine clinical procedures. All human samples were obtained after informed consent was provided by the subjects, in accordance with the Declaration of Helsinki and with the approval of the ethical review board of the Graduate School of Medicine, Osaka University, Japan (15383 and 752).
1. Whole Blood Sample Preparation and Staining
<ol>
	<li>Collect whole blood samples into blood collection tubes containing ethylene diamine tetra-acetic acid (EDTA). 
	NOTE: Blood collection can be performed using either a regular needle or a blood lancet.</li>
	<li>Transfer 20 &#181;L of whole blood samples to 5 mL round-bottom polystyrene flow cytometry tubes. 
	NOTE: To reduce non-specific binding of cells to tubes, 1 mL of 2% fetal bovine serum (FBS) in phosphate buffered saline (PBS) is added into tubes and vortexed for 10 s before application to samples.</li>
	<li>Add 20 &#181;L of 2% FBS in PBS.</li>
	<li>Add 10 &#181;L of human-specific FcR blocking reagent. Mix well and incubate for 15 min at room temperature.</li>
	<li>Add 500 &#181;L of red blood cell lysis buffer. Mix well and incubate for 10 min at room temperature.</li>
	<li>Add 4 mL of 2% FBS in PBS and spin down cells at 400 x g (1,500 rpm) for 5 min at 4 &#176;C. Remove supernatant by aspiration.</li>
	<li>Repeat the wash and aspiration process described in step 1.6.</li>
	<li>Re-suspend cells in 100 &#181;L of 2% FBS in PBS and divide into two tubes of 50 &#181;L each.</li>
	<li>Add surface marker antibodies (Table 1). Mix well and incubate for 20 min at room temperature in the dark. 
	NOTE: When profiling the T cell immune status, the number of markers can be increased based on the flow cytometry machine quality.</li>
	<li>Wash samples 2x as described in step 1.6.</li>
	<li>Resuspend cells in 200 &#181;L of 2% FBS in PBS.</li>
</ol>
2. Flow Cytometric Analysis
<ol>
	<li>Insert tubes into the flow cytometer and acquire cells, basically following the recommended protocol9.</li>
	<li>Record 10,000 events as the lymphocyte gate (Figure 1A) and export flow data as .fcs files for analysis.</li>
	<li>Open files in the analysis software. Visualize the cells on a forward scatter (FSC) (A) vs. side scatter (SSC) (A) plot and gate lymphocytes (Figure 1A).</li>
	<li>After selecting single cells using FSC (H) vs. FSC (W) and SSC (H) vs. SSC (W) (Figure 1B) and displaying them on a CD3 vs. CD8 or CD3 vs. CD4 plot, gate the CD8 T cells and CD4 T cells, respectively (Figure 1C).</li>
	<li>After selecting the gated cells and displaying them on a PD-1 vs. human IgG4 plot, identify PD-1&#8211;blocking antibody&#8211;bound CD8 and CD4 T cells based on isotype control (Figure 1D).</li>
</ol>

<ol><li>Gong, J., Chehrazi-Raffle, A., Reddi, S., Salgia, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+PD-1+and+PD-L1+inhibitors+as+a+form+of+cancer+immunotherapy%3A+a+comprehensive+review+of+registration+trials+and+future+considerations%5BTitle%5D)+AND+%22Journal+for+ImmunoTherapy+of+Cancer%22%5BJournal%5D)">Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.</a> Journal for ImmunoTherapy of Cancer. 6 (1), 8(2018).</li>
<li>Borghaei, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nivolumab+versus+Docetaxel+in+Advanced+Nonsquamous+Non-Small-Cell+Lung+Cancer%5BTitle%5D)+AND+%22The+New+England+Journal+of+Medicine%22%5BJournal%5D)">Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.</a> The New England Journal of Medicine. 373 (17), 1627-1639 (2015).</li>
<li>Brahmer, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nivolumab+versus+Docetaxel+in+Advanced+Squamous-Cell+Non-Small-Cell+Lung+Cancer%5BTitle%5D)+AND+%22The+New+England+Journal+of+Medicine%22%5BJournal%5D)">Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.</a> The New England Journal of Medicine. 373 (2), 123-135 (2015).</li>
<li>Herbst, R. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial%5BTitle%5D)+AND+%22The+Lancet%22%5BJournal%5D)">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.</a> The Lancet. 387 (10027), 1540-1550 (2016).</li>
<li>Postow, M. A., Sidlow, R., Hellmann, M. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune-Related+Adverse+Events+Associated+with+Immune+Checkpoint+Blockade%5BTitle%5D)+AND+%22The+New+England+Journal+of+Medicine%22%5BJournal%5D)">Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.</a> The New England Journal of Medicine. 378 (2), 158-168 (2018).</li>
<li>Weber, J. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Safety+Profile+of+Nivolumab+Monotherapy%3A+A+Pooled+Analysis+of+Patients+With+Advanced+Melanoma%5BTitle%5D)+AND+%22Journal+of+Clinical+Oncology%22%5BJournal%5D)">Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.</a> Journal of Clinical Oncology. 35 (7), 785-792 (2017).</li>
<li>Champiat, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Management+of+immune+checkpoint+blockade+dysimmune+toxicities%3A+a+collaborative+position+paper%5BTitle%5D)+AND+%22Annals+of+Oncology%22%5BJournal%5D)">Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.</a> Annals of Oncology. 27 (4), 559-574 (2016).</li>
<li>Brahmer, J. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Phase+I+study+of+single-agent+anti-programmed+death-1+%28MDX-1106%29+in+refractory+solid+tumors%3A+safety%2C+clinical+activity%2C+pharmacodynamics%2C+and+immunologic+correlates%5BTitle%5D)+AND+%22Journal+of+Clinical+Oncology%22%5BJournal%5D)">Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.</a> Journal of Clinical Oncology. 28 (19), 3167-3175 (2010).</li>
<li>Bommareddy, P. K., Lowe, D. B., Kaufman, H. L., Rabkin, S. D., Saha, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multi-parametric+flow+cytometry+staining+procedure+for+analyzing+tumor-infiltrating+immune+cells+following+oncolytic+herpes+simplex+virus+immunotherapy+in+intracranial+glioblastoma%5BTitle%5D)+AND+%22Journal+of+Biological+Methods%22%5BJournal%5D)">Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.</a> Journal of Biological Methods. 6 (2), 112(2019).</li>
<li>Osa, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clinical+implications+of+monitoring+nivolumab+immunokinetics+in+non-small+cell+lung+cancer+patients%5BTitle%5D)+AND+%22JCI+Insight%22%5BJournal%5D)">Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.</a> JCI Insight. 3 (19), 59125(2018).</li>
<li>Zelba, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Accurate+quantification+of+T-cells+expressing+PD-1+in+patients+on+anti-PD-1+immunotherapy%5BTitle%5D)+AND+%22Cancer+Immunology%2C+Immunotherapy%22%5BJournal%5D)">Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.</a> Cancer Immunology, Immunotherapy. 67 (12), 1845-1851 (2018).</li>
<li>Simoni, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bystander+CD8%28%2B%29+T+cells+are+abundant+and+phenotypically+distinct+in+human+tumour+infiltrates%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates.</a> Nature. 557 (7706), 575-579 (2018).</li>
<li>Chiu, H. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+a+general+method+for+quantifying+IgG-based+therapeutic+monoclonal+antibodies+in+human+plasma+using+protein+G+purification+coupled+with+a+two+internal+standard+calibration+strategy+using+LC-MS%2FMS%5BTitle%5D)+AND+%22Analytica+Chimica+Acta%22%5BJournal%5D)">Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS.</a> Analytica Chimica Acta. 1019, 93-102 (2018).</li>
</ol>

The authors have nothing to disclose.

In this article, we report a method using a flow cytometer to detect PD-1&#8211;blocking antibodies bound to T cells derived from a drop of peripheral blood, which we originally developed for nivolumab detection10. Although this technique is very simple and easy to perform, two important points should be noted in order to obtain accurate results. One is that to detect PD-1 molecules, an appropriate antibody that competes with nivolumab and pembrolizumab should be used. This issue was evaluated in ...

PD-1&#8211;blocking antibodies have become the standard choice for treatment of various types of cancer, including non-small cell lung cancer (NSCLC)1,2,3,4. They show a remarkable therapeutic effect in a subset of cancer patients who have not responded to conventional cytotoxic chemotherapies. However, immune checkpoint inhibitors (ICIs), which include PD-1&#8211;blocking antibodies, can cause a unique and distinct spectrum of adverse events, termed immune-related adverse events (irAEs)5. Although irAEs can affect almost all tissues, they are most commonly observed in the gastrointestinal tract, endocrine glands, skin, and liver, and they can cause pruritus, rash, nausea, diarrhea, and thyroid disorders6,7. In general, most irAEs appear within 1 to 2 months after the initiation of ICIs. However, in some cases, they can occur later than 1 year after the beginning of treatment or even after treatment cessation6,7. They also cause various symptoms that may be difficult to discriminate from other pathologies. Thus, it can be challenging to promptly diagnose irAEs and treat them appropriately. irAEs can affect all tissues, and their onset is strongly influenced by circulating immune cells, especially T cells bound to PD-1&#8211;blocking antibodies. Therefore, a straightforward and minimally invasive method to monitor antibody-targeted T cells is important in clinical settings.
Here, we developed a simple method to assess the binding of PD-1&#8211;blocking antibodies to T cells using a drop of peripheral whole blood from cancer patients who received nivolumab or pembrolizumab. Using this approach, we were able to monitor each of the following: 1) the duration of antibody binding to T cells, 2) the occupancy of T cell PD-1 molecules by therapeutic antibodies, and 3) the activation status and immunological features of T cells. This method is a modification of a previously reported technique8. The amount of blood required is almost the same as that needed for a glucose test, and the approach does not require mononuclear cell enrichment or co-culturing with PD-1&#8211;blocking antibodies. We confirmed that this method can also be performed using frozen samples, including peripheral blood mononuclear cells (PBMCs) and cells from pleural effusion, pericardial effusion, bronchoalveolar lavage fluid, and cerebrospinal fluid, suggesting that this strategy may be useful in the context of a multicenter study. This method may facilitate the early diagnosis of irAEs, and also help to determine the appropriate immunosuppressive treatments to control their symptoms and to identify the optimal times to initiate subsequent therapies after PD-1 inhibitors.

<table><tbody><tr><td>10X RBC Lysis Buffer (Multi-species)</td><td>Thermo Fisher Scientific</td><td>00-4300-54</td><td>50 mL</td></tr><tr><td>APC/Cyanine7 anti-human CD4 Antibody</td><td>BioLegend</td><td>300518</td><td>Clone RPA-T4</td></tr><tr><td>BD FACS Canto II Flow Cytometer</td><td>BD</td><td></td><td></td></tr><tr><td>Brilliant Violet 510 anti-human CD8a Antibody</td><td>BioLegend</td><td>301048</td><td>Clone RPA-T8</td></tr><tr><td>Dulbecco&#039;s Phosphate Buffered Saline</td><td>nacalai tesque</td><td>14249-95</td><td>500 mL</td></tr><tr><td>Falcon Round-Bottom Polystyrene Tubes</td><td>STEMCELL Technologies</td><td>352058</td><td>5 mL</td></tr><tr><td>FcR Blocking Reagent, human</td><td>Miltenyi Biotec</td><td>130-059-901</td><td>2 mL</td></tr><tr><td>FLOWJO</td><td>BD</td><td></td><td></td></tr><tr><td>Gibco Fetal Bovine Serum</td><td>Thermo Fisher Scientific</td><td>12676029</td><td>500 mL</td></tr><tr><td>Mouse IgG1 monoclonal - Isotype control</td><td>abcam</td><td>ab81200</td><td></td></tr><tr><td>Mouse monoclonal Anti-Human IgG4 Fc</td><td>abcam</td><td>ab99825</td><td>Clone HP6025</td></tr><tr><td>Pacific Blue Mouse Anti-Human CD3</td><td>BD</td><td>558117</td><td>Clone UCHT1</td></tr><tr><td>PE-Cy7 Mouse anti-Human CD279 (PD-1)</td><td>BD</td><td>561272</td><td>Clone EH12.1</td></tr><tr><td>PE-Cy7 Mouse IgG1 &amp;kappa; Isotype Control</td><td>BD</td><td>557646</td><td></td></tr></tbody></table>

monitoring pd-1-blocking antibodies bound to t cells derived from a drop of peripheral blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Immune checkpoint inhibitors, including PD-1&#8211;blocking antibodies, have significantly improved treatment outcomes in various types of cancer. The pharmacological efficacy of these immunotherapies is long lasting, extending even beyond the discontinuation of their injections, due to persistent blood concentrations. Here we developed a simple flow cytometry assay to evaluate the T cell binding status of the PD-1&#8211;blocking antibodies nivolumab and pembrolizumab. Like a glucose test, this assay requires just a single drop of peripheral blood. Visualizing antibody binding on T cells is more reliable than measuring antibody blood concentrations. In addition, if necessary, we can potentially analyze many distinctive immune-related markers on T cells bound to PD-1&#8211;blocking antibodies. Thus, this is a simple and minimally invasive strategy to analyze the pharmacological effect of PD-1&#8211;blocking antibodies in cancer patients.

The gating strategy and flow cytometry analysis (Figure 1) can detect PD-1–blocking antibody binding to T cells obtained from a drop of NSCLC patient peripheral blood. Before PD-1–blocking antibody is administered, no human IgG4-positive CD8 or CD4 T cells are present, and PD-1 expression can be confirmed by a PD-1–detecting antibody (EH12.1) (Figure 2A). After nivolumab or pembrolizumab administration, IgG4 (nivolumab, pembrolizumab) can be det...

We developed a simple flow cytometry assay for evaluating the binding of PD-1&#8211;blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer patients.

Immune checkpoint inhibitors, including PD-1&#8211;blocking antibodies, have significantly improved treatment outcomes in various types of cancer. The ...

monitoring-pd-1-blocking-antibodies-bound-to-t-cells-derived-from

Research

JoVE Journal

Medicine

This paper describes a simple technique to induce alloantigen-specific anergy in human peripheral blood mononuclear cells. The technique can be applied clinically to generate non-alloreactive donor cells. Infusion of these cells could improve immune reconstitution and reduce toxicity after allogeneic hematopoietic stem cell transplantation.

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

This video demonstrates a flow cytometry-based technique using two fluorochromes to identify CD4+ and CD8+ T cells, γδ T cells, B cells, natural killer (NK) cells, and monocytes in human peripheral blood mononuclear cells (PBMCs). Upon incubating the cells with fluorochrome-conjugated antibodies against the surface markers, the cell subsets are identified using an optimal flow cytometric gating strategy.

A Flow Cytometry Assay to Identify Immune Cell Subsets in Peripheral Blood Mononuclear Cells

Here we describe a protocol for isolating subsets of precursor B-cells from umbilical cord blood.  A sufficient quantity and quality of nucleic acids may be extracted from the cells and used in subsequent assays utilizing DNA or RNA.

Isolation of Precursor B-cell Subsets from Umbilical Cord Blood

We developed an in vitro assay to investigate the role of immunoregulatory pathways in the regulation of cytokine secretion by HIV-specific CD4 T cells.

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Presented here is a straightforward method for the isolation and flow cytometric analysis of glioma-infiltrating peripheral blood mononuclear cells that yields time-dependent quantitative data on the number and activation status of immune cells entering the early brain tumor microenvironment.

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

The protocol describes a technique to study the ability of primary polyclonal human T cells to form synaptic interfaces using planar lipid bilayers. We use this technique to show the differential synapse formation capability of human primary T cells derived from lymph nodes and peripheral blood.

Assessment of the Synaptic Interface of Primary Human T Cells from Peripheral Blood and Lymphoid Tissue

The characterization of circulating tumor cells (CTCs) is a popular topic in translational research. This protocol describes a semi-automatic immunofluorescence (IF) assay for PD-L1 characterization and enumeration of CTCs in non-small cell lung cancer (NSCLC) patient samples.

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

This protocol details clinically implementable preparation of high quality PBMC and plasma biosamples at the clinical trial site that can be used for translational biomarker analysis.

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

The use of cytokine release assay reference reagents allows for more reproducible and standardized in vitro safety profiles of immunotherapeutic monoclonal antibodies. Here we describe how cytokine release assays can be used alongside a reference reagent panel to predict the safety of some therapeutic monoclonal antibodies.

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Checkpoint inhibitors are important targets in developing therapies for the battle against cancer. This report introduces a novel PDL1 peptide-based cancer vaccine, PDL1-Vaxx, which induces neutralizing polyclonal antibody production that blocks PD-1/PDL1 complex formation. This work also details the development and testing of a fluorescent bead-based assay for analyzing this activity.

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

This protocol describes a blockade assay for PD-1/PD-L1 inhibitors using surface plasmon resonance technology. It employs a dual-step immobilization strategy and a tailored buffer system to accurately measure response units, facilitating the assessment of blockade rates for compounds or biologics. Additionally, it supports the high-throughput identification of PD-1/PD-L1 inhibitors.

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Learn a flow cytometry assay to evaluate PD-1-blocking antibody binding to T cells using minimal peripheral blood from cancer patients. This method identifies immune subsets linked to therapeutic effects and adverse events.

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Explore More Videos